Drug-resistant malaria is beating our best antimalarial drug, and this isn’t the first time. Just last week a report in the New England Journal of Medicine detailed the extent to which resistance to the current first-line antimalarial drug artemisinin has spread from its epicenter, the Thai-Cambodia border. This study conducted by researchers from different institutions, collectively known as the Tracking Resistance to Artemisinin Collaboration (TRAC), monitored artemisinin resistance from 2011 to 2013 across 10 countries — primarily in Southeast Asia, but also in South Asia and sub-Saharan Africa.